PROM1, CXCL8, RUNX1, NAV1 and TP73 genes as independent markers predictive of prognosis or response to treatment in two cohorts of high-grade serous ovarian cancer patients.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Cystadenocarcinoma, Serous*/drug therapy ; Cystadenocarcinoma, Serous*/genetics ; Ovarian Neoplasms*/drug therapy ; Ovarian Neoplasms*/therapy; AC133 Antigen ; Biomarkers ; Core Binding Factor Alpha 2 Subunit ; Female ; Humans ; Prognosis
    • Abstract:
      Considering the vast biological diversity and high mortality rate in high-grade ovarian cancers, identification of novel biomarkers, enabling precise diagnosis and effective, less aggravating treatment, is of paramount importance. Based on scientific literature data, we selected 80 cancer-related genes and evaluated their mRNA expression in 70 high-grade serous ovarian cancer (HGSOC) samples by Real-Time qPCR. The results were validated in an independent Northern American cohort of 85 HGSOC patients with publicly available NGS RNA-seq data. Detailed statistical analyses of our cohort with multivariate Cox and logistic regression models considering clinico-pathological data and different TP53 mutation statuses, revealed an altered expression of 49 genes to affect the prognosis and/or treatment response. Next, these genes were investigated in the validation cohort, to confirm the clinical significance of their expression alterations, and to identify genetic variants with an expected high or moderate impact on their products. The expression changes of five genes, PROM1, CXCL8, RUNX1, NAV1, TP73, were found to predict prognosis or response to treatment in both cohorts, depending on the TP53 mutation status. In addition, we revealed novel and confirmed known SNPs in these genes, and showed that SNPs in the PROM1 gene correlated with its elevated expression.
      Competing Interests: The authors have declared that no competing interests exist.
    • References:
      J Leukoc Biol. 1994 Nov;56(5):559-64. (PMID: 7964163)
      Oncogenesis. 2020 Feb 6;9(2):12. (PMID: 32029709)
      Biochem Pharmacol. 2020 Oct;180:114116. (PMID: 32579960)
      Biom J. 2008 Aug;50(4):457-79. (PMID: 18663757)
      Stem Cells. 2015 Apr;33(4):1304-19. (PMID: 25524638)
      Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):220-5. (PMID: 25535357)
      J Exp Clin Cancer Res. 2015 Oct 09;34:117. (PMID: 26452645)
      Hum Mol Genet. 2010 Nov 1;19(21):4273-7. (PMID: 20724461)
      J Cell Mol Med. 2020 Jan;24(2):1588-1598. (PMID: 31793192)
      Genome Biol. 2002 Jun 18;3(7):RESEARCH0034. (PMID: 12184808)
      Cancer. 1981 Jan 1;47(1):207-14. (PMID: 7459811)
      Gynecol Oncol. 2013 Feb;128(2):356-63. (PMID: 23219462)
      Signal Transduct Target Ther. 2021 Feb 24;6(1):78. (PMID: 33623018)
      Mol Cell Neurosci. 2005 Apr;28(4):599-612. (PMID: 15797708)
      Cell Physiol Biochem. 2014;34(6):2209-20. (PMID: 25562167)
      Mod Pathol. 2012 Mar;25(3):456-64. (PMID: 22080056)
      Nat Genet. 2003 Jan;33(1):49-54. (PMID: 12469122)
      PLoS One. 2010 Feb 15;5(2):e9201. (PMID: 20169162)
      Front Genet. 2020 Mar 05;11:109. (PMID: 32211018)
      Genome Biol. 2016 Jun 06;17(1):122. (PMID: 27268795)
      Nat Commun. 2017 Oct 17;8(1):990. (PMID: 29042553)
      Oncotarget. 2015 Oct 13;6(31):31593-603. (PMID: 26267317)
      J Cell Mol Med. 2017 Mar;21(3):510-518. (PMID: 28233473)
      Oncogene. 2008 Feb 14;27(8):1183-8. (PMID: 17700524)
      Hum Mutat. 2014 Jun;35(6):654-62. (PMID: 24706533)
      Bioinformatics. 2014 Feb 01;30(3):301-4. (PMID: 24319002)
      Nat Cell Biol. 2015 Apr;17(4):511-23. (PMID: 25774835)
      Elife. 2014 Nov 21;3:e03881. (PMID: 25415051)
      Oncol Lett. 2019 Feb;17(2):2365-2369. (PMID: 30719112)
      Coll Antropol. 2015 Sep;39(3):745-53. (PMID: 26898076)
      J Biol Chem. 2005 Oct 7;280(40):34159-69. (PMID: 16087678)
      Mol Oncol. 2009 Apr;3(2):171-81. (PMID: 19383379)
      Br J Cancer. 2004 Nov 29;91(11):1916-23. (PMID: 15545967)
      Genome Biol. 2007;8(2):R19. (PMID: 17291332)
      Cancer Res. 2012 Sep 1;72(17):4383-93. (PMID: 22751462)
      Nature. 2020 Feb;578(7793):82-93. (PMID: 32025007)
      Am J Obstet Gynecol. 1975 Mar 15;121(6):795-807. (PMID: 1092171)
      PLoS One. 2011;6(12):e28403. (PMID: 22220191)
      Chin Clin Oncol. 2020 Aug;9(4):47. (PMID: 32648448)
      Breast Cancer Res. 2011 Oct 06;13(5):R97. (PMID: 21978456)
      Clin Transl Med. 2018 Jul 9;7(1):18. (PMID: 29984391)
      Nat Struct Mol Biol. 2009 Feb;16(2):107-13. (PMID: 19190664)
      Nat Cell Biol. 2013 Jan;15(1):2-8. (PMID: 23263379)
      Cytokine. 2012 Jul;59(1):145-55. (PMID: 22579115)
      J Cell Physiol. 2015 Oct;230(10):2522-32. (PMID: 25802202)
      J Mol Biol. 2017 Jun 2;429(11):1595-1606. (PMID: 28390900)
      J Cell Sci. 2019 Oct 3;132(19):. (PMID: 31582429)
      FEBS J. 2017 Aug;284(15):2345-2362. (PMID: 28304148)
      Zhonghua Bing Li Xue Za Zhi. 2012 Jan;41(1):33-8. (PMID: 22455848)
      Exp Ther Med. 2019 Jul;18(1):389-396. (PMID: 31258677)
      Clin Cancer Res. 2000 Oct;6(10):3910-5. (PMID: 11051237)
      Nucleic Acids Res. 2021 Jan 8;49(D1):D545-D551. (PMID: 33125081)
      Anticancer Res. 2006 Sep-Oct;26(5B):3633-43. (PMID: 17094378)
      Cell Cycle. 2013 Mar 15;12(6):972-86. (PMID: 23442798)
      Bioinformatics. 2012 Jul 1;28(13):1805-6. (PMID: 22543366)
      BMC Cancer. 2008 Jan 29;8:27. (PMID: 18230133)
      Ann Hum Genet. 2006 Sep;70(Pt 5):594-604. (PMID: 16907706)
      Oncogene. 2011 Oct 13;30(41):4219-30. (PMID: 21516125)
      FEBS Lett. 2014 Aug 19;588(16):2590-9. (PMID: 24983500)
      Cold Spring Harb Protoc. 2015 Apr 13;2015(11):951-69. (PMID: 25870306)
      Int J Cancer. 2005 Jan 10;113(2):221-8. (PMID: 15386419)
      Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
      Mol Med Rep. 2019 Mar;19(3):2317-2322. (PMID: 30747214)
      Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):395-404. (PMID: 28615364)
      Hum Mutat. 2014 Jun;35(6):702-14. (PMID: 24488880)
      PLoS One. 2014 Jun 26;9(6):e100759. (PMID: 24967588)
      Nucleic Acids Res. 2021 Jan 8;49(D1):D480-D489. (PMID: 33237286)
      Oncotarget. 2018 Apr 3;9(25):17735-17755. (PMID: 29707144)
      Cancer Gene Ther. 2020 Apr;27(3-4):147-167. (PMID: 31164716)
      Circ Genom Precis Med. 2019 Oct;12(10):e002617. (PMID: 32141789)
      Cancer Growth Metastasis. 2018 Apr 09;11:1179064418767882. (PMID: 29662326)
      Cell. 1996 Jan 26;84(2):321-30. (PMID: 8565077)
      Nat Rev Cancer. 2014 May;14(5):359-70. (PMID: 24739573)
      Br J Cancer. 2003 Mar 24;88(6):848-54. (PMID: 12644821)
      Clin Transl Oncol. 2015 May;17(5):365-70. (PMID: 25373532)
      Cell. 2008 Jul 11;134(1):62-73. (PMID: 18614011)
      Cell Death Differ. 2021 Dec;28(12):3357-3370. (PMID: 34183782)
      Cancer Res. 2001 Feb 1;61(3):935-8. (PMID: 11221886)
      J Immunol. 2000 Mar 1;164(5):2769-75. (PMID: 10679119)
      Nat Rev Cancer. 2005 May;5(5):376-87. (PMID: 15864279)
      Oncotarget. 2016 Oct 11;7(41):67412-67424. (PMID: 27602952)
    • Accession Number:
      0 (AC133 Antigen)
      0 (Biomarkers)
      0 (Core Binding Factor Alpha 2 Subunit)
      0 (PROM1 protein, human)
      0 (RUNX1 protein, human)
    • Publication Date:
      Date Created: 20220722 Date Completed: 20220726 Latest Revision: 20220728
    • Publication Date:
      20240829
    • Accession Number:
      PMC9307210
    • Accession Number:
      10.1371/journal.pone.0271539
    • Accession Number:
      35867729